Navigation Links
Louisiana State University Health Sciences Center research discovers key to survival of brain cells
Date:9/28/2011

New Orleans, LA -- Nicolas G. Bazan, MD, Ph.D, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center New Orleans, and David Stark, an MD/Ph.D student working in his lab, have discovered how a key chemical neurotransmitter that interacts with two receptors in the brain promotes either normal function or a disease process -- determining whether brain cells live or die. The work is published and highlighted in the September 28, 2011 issue of the Journal of Neuroscience.

These findings reveal how receptor signaling takes place between receptors of synapses (gaps between neurons through which chemical or electrical signals pass permitting cells to "talk" to each other) and the mechanisms involved in initiating disease. The receptors, called NMDARs, are located both inside and outside of the synapses. Activation of the NMDRs inside (synaptic) allows the synapse to adjust response to signals and activation of the synaptic NMDRs is also required for survival of the cell. In contrast, activation of the receptors outside the synapse (extrasynaptic) leads to cell death.

The LSUHSC research team believed that activation of the extrasynaptic NMDRs promotes the pathological effects of cyclooxygenase 2 (COX-2), a protein known to contribute to inflammation associated with neurotoxicity. They found that activating the synaptic NMDRs greatly increased levels of COX-2, but not of the chemical (arachidonic acid) upon which COX-2 acts. Conversely, activating the extrasynaptic NMDRs increased the levels of arachidonic acid, but not COX-2. The researchers discovered, however, when synaptic and extrasynaptic NMDARs were sequentially activated, the levels of both COX-2 and arachidonic acid increased, as did neurotoxic inflammation.

"We have discovered a fascinating relationship regarding the "conversations" that occur between these two receptors in the brain," said Dr. Nicolas G. Bazan, Professor and Director, LSUHSC Neuroscience Center of Excellence.

"In this paper, we demonstrate how these signals affect cell functions and how they lead to diseases, including stroke, epilepsy and other neurodegenerative disorders. Targeting mechanisms that couple sequential synaptic then extrasynaptic NMDAR stimulations may lead to new anti-inflammatory/neuroprotective approaches."

The research was supported by grants from the National Institutes of Health, National Institute of Neurological Disorders and Stroke, National Center for Research Resources, and the National Center for Complementary and Alternative Medicine.

"I have a very gifted and talented young MD/Ph.D student in my lab, David Stark, who has a National Institutes of Health award, performed exemplary experiments and co-authored the paper with me," said Dr. Bazan.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related medicine news :

1. Louisiana State University Health Sciences Center research shows fish oil component given up to 5 hours after stroke limits brain damage
2. Louisiana Tech kinesiology professor receives national editorial excellence award
3. Louisiana's First DNP Program Kicks Off Classes at Loyola University New Orleans
4. Louisiana Tech students, faculty earn accolades from Louisiana Dietetic Association
5. Louisiana Law Firm Neblett, Beard & Arsenault Launches New Foodborne Illness Site
6. New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; Louisiana is 46th Among All States in Maternal Mortality
7. Pew Report: Louisiana Failing to Address Childrens Dental Health Crisis
8. SHARECOR Partners With Quantros, Inc. to Facilitate Core Measures and Regulatory Reporting in Louisiana Hospitals
9. Gene may be good target for tough-to-kill prostate cancer cells
10. New UC research promises better collection of prostate cancer cells
11. Saw Palmetto Doesnt Help Enlarged Prostate: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... United Benefit Advisors (UBA), ... as the latest addition to its family of Partner Firms. Headquartered in Mount ... wellness, human resources, and health care consumerism specialists. , “Partnering with UBA will ...
(Date:5/5/2016)... ... May 05, 2016 , ... An essential ... U.S. states and certain Canadian provinces is now available from the International Association ... (WCRI). , The report, Workers’ Compensation Laws as of January 1, ...
(Date:5/5/2016)... Chicago, IL (PRWEB) , ... May 05, 2016 , ... ... that employers continue to face challenges in getting employees to understand and use the ... (ACA). One of the nation’s leading non-profit business groups of large, self-insured public and ...
(Date:5/5/2016)... ... May 05, 2016 , ... Vitenas Cosmetic Surgery has been ... presented by the American Institute of Architects and the Academy of Architecture for Health. ... Perkins+Will and Harrell Architects, opened to patients in October of 2014. ...
(Date:5/5/2016)... ... 2016 , ... TIME for Kids and The ZAC Foundation – a national ... reach nearly 1 million children with important water safety messages before summer break begins. ... of accidental death in children one to 6 years of age. TIME for ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... DUBLIN , May 5, 2016 /PRNewswire/ ... the addition of the  "Europe Systemic Lupus ... 2016"  report to their offering.  ... The latest research Europe Systemic Lupus ... 2016, provides comprehensive insights into Systemic Lupus ...
(Date:5/4/2016)... Israel , May 4, 2016 ... BiondVax,s CEO, Dr. Ron Babecoff , will be attending ... York City . On Thursday, May 5, ... a conference presented by Joseph Gunner & Co, ... The BiondVax presentation that Dr. Babecoff will be using is ...
(Date:5/4/2016)... , May 4, 2016 Valeritas ... of an alternative public offering (APO). This was accomplished ... company, Valeritas, Inc. and a private placement of approximately ... $5.00 per share. Under the terms of ... 2016, Valeritas Holdings, Inc. will trade on the OTC ...
Breaking Medicine Technology: